| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Esafoxolaner primarily targets ligand-gated chloride channels, particularly GABA-gated chloride channels in the nervous system of insects and acarines. By blocking these channels, it inhibits the influx of chloride ions, leading to hyperexcitation of the nervous system, paralysis, and death of the parasite. Esafoxolaner is selective for invertebrate chloride channels over mammalian channels, contributing to its safety profile.
|
|---|---|
| ln Vitro |
In vitro, Esafoxolaner blocks GABA-gated chloride channels in insect and acarine neurons. It shows high potency against fleas (Ctenocephalides felis) and ticks (Ixodes ricinus, Rhipicephalus sanguineus). The compound is highly lipophilic and accumulates in the nervous tissue of parasites.
|
| ln Vivo |
In vivo, Esafoxolaner is effective against flea and tick infestations in cats. It is administered topically as a spot-on formulation. The compound is rapidly absorbed through the skin and distributed systemically. Esafoxolaner provides long-lasting protection against reinfestation for at least one month. It is well-tolerated in cats at recommended doses.
|
| Enzyme Assay |
For chloride channel assays, membrane preparations from insect neurons or recombinant chloride channels are incubated with Esafoxolaner, and chloride flux is measured using radiolabeled chloride or fluorescent dyes. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro parasite assays, fleas or ticks are exposed to Esafoxolaner-treated surfaces or blood, and mortality is recorded. For cell-based assays, insect neuronal cells are treated with Esafoxolaner, and membrane potential changes are measured using fluorescent dyes.
|
| Animal Protocol |
For in vivo studies, cats infested with fleas or ticks are treated topically with Esafoxolaner at recommended doses. Parasite counts are performed at various time points after treatment. For pharmacokinetic studies, plasma levels of Esafoxolaner are quantified by LC-MS/MS.
|
| Additional Infomation |
See also: eplerenone; essaforana; praziquantel (component).
|
| Molecular Formula |
C26H17CLF9N3O3
|
|---|---|
| Molecular Weight |
625.870116949081
|
| Exact Mass |
625.081
|
| CAS # |
1096103-99-9
|
| Related CAS # |
1093861-60-9 (Afoxolaner);1096103-99-9 (Esafoxolaner);
|
| PubChem CID |
76961292
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.7
|
| tPSA |
79.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
42
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1C(=NO[C@@]1(C2=CC(=CC(=C2)Cl)C(F)(F)F)C(F)(F)F)C3=CC=C(C4=CC=CC=C43)C(=O)NCC(=O)NCC(F)(F)F
|
| InChi Key |
OXDDDHGGRFRLEE-QHCPKHFHSA-N
|
| InChi Code |
InChI=1S/C26H17ClF9N3O3/c27-15-8-13(7-14(9-15)25(31,32)33)23(26(34,35)36)10-20(39-42-23)18-5-6-19(17-4-2-1-3-16(17)18)22(41)37-11-21(40)38-12-24(28,29)30/h1-9H,10-12H2,(H,37,41)(H,38,40)/t23-/m0/s1
|
| Chemical Name |
4-[(5S)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5978 mL | 7.9889 mL | 15.9778 mL | |
| 5 mM | 0.3196 mL | 1.5978 mL | 3.1956 mL | |
| 10 mM | 0.1598 mL | 0.7989 mL | 1.5978 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.